| Aggregate Evidence Quality . | Grade B . |
|---|---|
| Benefits | Improved 24-h control of BP improves outcomes. Recognition of MH or nocturnal HTN might lead to therapeutic changes that will limit end organ damage |
| Risks, harm, cost | Risk of discomfort to patient. Some insurance plans may not reimburse for the test. The risk of diagnosing and labeling a patient as having MH or nocturnal HTN might lead to increased anxiety and cost of evaluation |
| Benefit–harm assessment | The risk of ABPM is much lower than the risk of inadequate treatment |
| Intentional vagueness | Frequency at which normal or abnormal ABPM should be repeated is not known |
| Role of patient preferences | Some patients may prefer repeat office or home measurements to ABPM |
| Exclusions | None |
| Strength | Moderate recommendation |
| Key references | 47,155,199–202 |
| Aggregate Evidence Quality . | Grade B . |
|---|---|
| Benefits | Improved 24-h control of BP improves outcomes. Recognition of MH or nocturnal HTN might lead to therapeutic changes that will limit end organ damage |
| Risks, harm, cost | Risk of discomfort to patient. Some insurance plans may not reimburse for the test. The risk of diagnosing and labeling a patient as having MH or nocturnal HTN might lead to increased anxiety and cost of evaluation |
| Benefit–harm assessment | The risk of ABPM is much lower than the risk of inadequate treatment |
| Intentional vagueness | Frequency at which normal or abnormal ABPM should be repeated is not known |
| Role of patient preferences | Some patients may prefer repeat office or home measurements to ABPM |
| Exclusions | None |
| Strength | Moderate recommendation |
| Key references | 47,155,199–202 |